Literature DB >> 25515559

Role of the ERK1/2 pathway in tumor chemoresistance and tumor therapy.

Qing-Hua Liu1, Mei-Lin Shi2, Chao Sun2, Jin Bai3, Jun-Nian Zheng4.   

Abstract

Chemotherapy is one of the important methods for treatment in tumors. However, many tumor patients may experience tumor recurrence because of treatment failure due to chemoresistance. Although many signaling pathways could influence chemoresistance of tumor cells, the extracellular signal-regulated kinase 1 and 2 (ERK1/2) pathway has gained significant attention because of its implications in signaling and which has crosstalk with other signaling pathways. Extensive studies conclude that ERK1/2 pathway is responding to chemoresistance in many kinds of malignant tumors. The aim of this review is to discuss on the role of ERK1/2 pathway in chemoresistance and therapy of tumors. A comprehensive understanding of ERK1/2 pathway in chemoresistance of tumors could provide novel avenues for treatment strategies of tumors.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ERK1/2; MEK; Raf; Ras; Tumor chemoresistance; Tumor therapy

Mesh:

Substances:

Year:  2014        PMID: 25515559     DOI: 10.1016/j.bmcl.2014.11.076

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  7 in total

1.  5FU/Oxaliplatin-Induced Jagged1 Cleavage Counteracts Apoptosis Induction in Colorectal Cancer: A Novel Mechanism of Intrinsic Drug Resistance.

Authors:  Maria Pelullo; Sabrina Zema; Mariangela De Carolis; Samantha Cialfi; Maria Valeria Giuli; Rocco Palermo; Carlo Capalbo; Giuseppe Giannini; Isabella Screpanti; Saula Checquolo; Diana Bellavia
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

2.  A Novel Class of Common Docking Domain Inhibitors That Prevent ERK2 Activation and Substrate Phosphorylation.

Authors:  Rachel M Sammons; Nicole A Perry; Yangmei Li; Eun Jeong Cho; Andrea Piserchio; Diana P Zamora-Olivares; Ranajeet Ghose; Tamer S Kaoud; Ginamarie Debevec; Chandra Bartholomeusz; Vsevolod V Gurevich; Tina M Iverson; Marc Giulianotti; Richard A Houghten; Kevin N Dalby
Journal:  ACS Chem Biol       Date:  2019-05-13       Impact factor: 5.100

Review 3.  Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma.

Authors:  Amir Mehdizadeh; Mohammad Hossein Somi; Masoud Darabi; Mortaza Jabbarpour-Bonyadi
Journal:  Mol Biol Rep       Date:  2016-01-14       Impact factor: 2.316

4.  Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers.

Authors:  Dena A J Ahmad; Ola H Negm; M Layth Alabdullah; Sameer Mirza; Mohamed R Hamed; Vimla Band; Andrew R Green; Ian O Ellis; Emad A Rakha
Journal:  Breast Cancer Res Treat       Date:  2016-09-03       Impact factor: 4.872

Review 5.  The molecular mechanisms of chemoresistance in cancers.

Authors:  Hua-Chuan Zheng
Journal:  Oncotarget       Date:  2017-07-06

6.  Pyruvate Dehydrogenase Contributes to Drug Resistance of Lung Cancer Cells Through Epithelial Mesenchymal Transition.

Authors:  Buse Cevatemre; Engin Ulukaya; Egemen Dere; Sukru Dilege; Ceyda Acilan
Journal:  Front Cell Dev Biol       Date:  2022-01-04

7.  Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma.

Authors:  Alexandre Benoit; Elisabeth Bou-Petit; Hsiang Chou; Melissa Lu; Cynthia Guilbert; Vincent Mingyi Luo; Sarit Assouline; Ryan D Morin; Svetlana Dmitrienko; Roger Estrada-Tejedor; Nathalie A Johnson; Koren K Mann
Journal:  Sci Rep       Date:  2022-01-17       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.